These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 28144840

  • 1. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
    Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, de Lange DW, Pickkers P, Brüggemann RJ.
    Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E, Grau S, Luque S, Castillo-Mafla MP, Suárez-de-la-Rica A, Montero-Feijoo A, Salgado P, Gimenez MJ, García-Bernedo CA, Gilsanz F, Roberts JA.
    Crit Care; 2018 Apr 15; 22(1):94. PubMed ID: 29655372
    [Abstract] [Full Text] [Related]

  • 3. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration.
    Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofiño A, Roberts JA, Aguilar L, Luque S, Sevillano D, Gimenez MJ, Gilsanz F.
    J Antimicrob Chemother; 2014 Jun 15; 69(6):1624-32. PubMed ID: 24505092
    [Abstract] [Full Text] [Related]

  • 4. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.
    Martial LC, Brüggemann RJ, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Muilwijk EW, Verweij PE, Burger DM, Aarnoutse RE, Pickkers P, Dorlo TP.
    Clin Pharmacokinet; 2016 Jun 15; 55(6):723-33. PubMed ID: 26649870
    [Abstract] [Full Text] [Related]

  • 5. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K, Nomura K, Morikawa N, Ikeda K, Taniwaki M.
    J Antimicrob Chemother; 2009 Oct 15; 64(4):840-4. PubMed ID: 19700475
    [Abstract] [Full Text] [Related]

  • 6. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
    Pérez-Pitarch A, Ferriols-Lisart R, Aguilar G, Ezquer-Garín C, Belda FJ, Guglieri-López B.
    Int J Antimicrob Agents; 2018 Jan 15; 51(1):115-121. PubMed ID: 28666752
    [Abstract] [Full Text] [Related]

  • 7. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
    Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM.
    Antimicrob Agents Chemother; 2011 May 15; 55(5):2113-21. PubMed ID: 21300835
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
    Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet JL, Bruneel F, Cour M, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou JC, Foucrier A, Allaouchiche B, Das V, Gangneux JP, Ruckly S, Wolff M, Timsit JF, EMPIRICUS Trial Study Group.
    J Antimicrob Chemother; 2017 Jan 15; 72(1):181-189. PubMed ID: 27609051
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.
    Antimicrob Agents Chemother; 2017 Dec 15; 61(12):. PubMed ID: 28971861
    [Abstract] [Full Text] [Related]

  • 10. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
    García-de-Lorenzo A, Luque S, Grau S, Agrifoglio A, Cachafeiro L, Herrero E, Asensio MJ, Sánchez SM, Roberts JA.
    Antimicrob Agents Chemother; 2016 Oct 15; 60(10):5914-21. PubMed ID: 27458229
    [Abstract] [Full Text] [Related]

  • 11. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
    Grau S, Luque S, Campillo N, Samsó E, Rodríguez U, García-Bernedo CA, Salas E, Sharma R, Hope WW, Roberts JA.
    J Antimicrob Chemother; 2015 Oct 15; 70(10):2854-61. PubMed ID: 26180134
    [Abstract] [Full Text] [Related]

  • 12. Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis.
    Zhong S, Zhu X, Zhao L, Song Y, Yu J, Zheng Z, Zang B.
    Pharm Res; 2021 Jan 15; 38(1):67-77. PubMed ID: 33404989
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetics of micafungin in neonates and young infants.
    Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK.
    Antimicrob Agents Chemother; 2010 Jun 15; 54(6):2633-7. PubMed ID: 20308367
    [Abstract] [Full Text] [Related]

  • 14. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
    Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM, Verweij PE, Pickkers P, Brüggemann RJ.
    Antimicrob Agents Chemother; 2015 Aug 15; 59(8):4403-9. PubMed ID: 25963988
    [Abstract] [Full Text] [Related]

  • 15. Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.
    Lu X, Xu G, Chen L, Fan J, Li M, Zhu L.
    Eur J Clin Pharmacol; 2020 May 15; 76(5):695-702. PubMed ID: 32047965
    [Abstract] [Full Text] [Related]

  • 16. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G, Zhu L, Liao S, Ge T, Yang J.
    Int J Antimicrob Agents; 2015 Dec 15; 46(6):631-41. PubMed ID: 26602452
    [Abstract] [Full Text] [Related]

  • 17. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM.
    Biol Blood Marrow Transplant; 2010 Oct 15; 16(10):1458-62. PubMed ID: 20546908
    [Abstract] [Full Text] [Related]

  • 18. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R, Petraitis V, Hope WW, Walsh TJ.
    Clin Infect Dis; 2015 Dec 01; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.